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the CC BY-NC-ND license (http://creaAbstract The therapies available for prostate cancer patients whom progress from hormone-
sensitive to castration resistant prostate cancer include both systemic drugs, including doce-
taxel and cabazitaxel, and drugs that inhibit androgen signaling such as enzalutamide and abir-
aterone. Unfortunately, it is estimated that up to 30% of patients have primary resistance to
these treatments and over time even those who initially respond to therapy will eventually
develop resistance and their disease will continue to progress regardless of the presence of
the drug. Determining the mechanisms involved in the development of resistance to these
therapies has been the area of intense study and several adaptive pathways have been uncov-
ered. Androgen receptor (AR) mutations, expression of AR-V7 (or other constitutively active
androgen receptor variants), intracrine androgen production and overexpression of androgen
synthesis enzymes such as Aldo-Keto Reductase Family 1, Member C3 (AKR1C3) are among
the many mechanisms associated with resistance to anti-androgens. In regards to the taxanes,
one of the key contributors to drug resistance is increased drug efflux through ATP Binding
Cassette Subfamily B Member 1 (ABCB1). Targeting these resistance mechanisms using
different strategies has led to various levels of success in overcoming resistance to current
therapies. For instance, targeting AR-V7 with niclosamide or AKR1C3 with indomethacin can
improve enzalutamide and abiraterone treatment. ABCB1 transport activity can be inhibited
by the dietary constituent apigenin and antiandrogens such as bicalutamide which in turn im-
proves response to docetaxel. A more thorough understanding of how drug resistance develops
will lead to improved treatment strategies. This review will cover the current knowledge of
resistance mechanisms to castration resistant prostate cancer therapies and methods that
have been identified which may improve treatment response.of Urology, University of California Davis Medical Center, 4645 2nd Ave, Research III, Suite 1300,
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Prostate cancer is the second leading cause of cancer
related deaths and the most commonly diagnosed cancer in
men with an estimated 220,800 new cases yearly in the
United States [1,2]. First line treatments for prostate can-
cer aim to reduce circulating androgen levels through the
use of androgen deprivation therapies (ADT). This is
accomplished using one of two methods: surgical bilateral
orchiectomy which inhibits androgen synthesis by the testes
or through the use of castration inducing drugs to reduce
androgen levels and androgen receptor (AR) activation.
While ADT is initially effective at reducing prostate cancer
growth, after 2e3 years of treatment the majority of pa-
tients will progress to castration resistant prostate cancer
(CRPC) and tumor growth will proceed even in the presence
of castrate levels of androgen. At this point of disease
progression, the number of therapeutic options is currently
limited but is the focus of intense research to improve the
outcome for patients [3].
Clinically, CRPC is defined as progression of prostate
cancer in the presence of castrate levels of circulating
testosterone [4,5]. Often times, the AR is either overex-
pressed, hyper-activated, or both leading to the tran-
scription of downstream target genes which ultimately
promotes tumor progression despite the patient having
negligible levels of androgen present. The mechanisms
which lead to the development of CRPC from hormone-
sensitive prostate cancer are widely studied. The identi-
fied mechanisms, including AR amplification and mutation,
AR co-activator and co-repressor modifications, aberrantxperimental (red) therapies for
receptor variants; CRPC, castraactivation and/or post-translational modification, AR splice
variants, and altered steroidogenesis, each results in an
increase in AR activation and signaling. This can be due to
an increased amount of androgen, enhanced response to
existing androgen, and activation of the AR by non-classical
ligands or no ligand at all among other methods [6e10].
Treatment of CRPC is currently achieved with the
administration of taxanes, such as docetaxel and cab-
azitaxel, which interrupt the growth of fast-dividing cells
through disruption of microtubule function, or with anti-
androgen therapies including enzalutamide and abirater-
one. The primary mechanism of anti-androgens is to inhibit
AR activation either directly, by antagonizing the receptor,
or indirectly by blocking androgen synthesis. Unfortunately,
it is estimated that one third of patients given abiraterone
and one fourth of patients given enzalutamide will fail to
respond to initial treatment with these drugs [11,12].
Furthermore, within 24 months of initiating treatment,
even those who initially respond to the drugs will develop
resistance.
New methods by which treatment resistance develops in
prostate cancer are constantly being identified. Due to the
numerous dysregulated pathways that are implicated in
prostate cancer drug resistance, elucidating ways to
reverse this resistance becomes both increasingly compli-
cated and important. This review will outline the current
understanding of the major compensatory mechanisms that
prostate cancer cells use to overcome the presence of the
drugs (Fig. 1). In addition, successful experimental strate-
gies that have been observed to improve treatment
response will be discussed (Fig. 2).CRPC and their targets. AR, androgen receptor; ARE, androgen-
tion resistant prostate cancer; DHT, dihydrotestosterone; PSA,
Figure 2 An overview of CRPC drug resistance and promising experimental inhibitors that target resistance mechanisms. ABCB1,
ATP Binding Cassette Subfamily B Member 1; AKR1C3, Aldo-Keto Reductase Family 1, Member C3; AR, androgen receptor; CRPC,
castration resistant prostate cancer; GR, glucocorticoid receptor.
Overcoming resistance in CRPC 1872. Current CRPC therapies
2.1. Anti-androgens
Anti-androgens seek to slow cancer cell growth by blocking
activation of the AR. Despite the ability CRPC cells gain to
bypass testosterone using the 5a-dione pathway to produce
the more biologically active dihydrotestosterone (DHT),
these cells still heavily rely on adrenal androgens which are
converted to androstenedione by 3bHSD in the prostate or
adrenal gland. DHT is then synthesized from androstenedi-
one. Abiraterone acetate functions by reducing circulating
androgens by inhibiting CYP17A1 and blocking the conversion
of pregnenolone to DHT. The net result is a loss of androgen
synthesis in peripheral tissues as well as a reduction in the
precursors required for intratumoral androgen production.
In addition to inhibition of CYP17A1, studies have observed
that abiraterone can be converted into the more active D4-
abiraterone (D4A) and this formof the anti-androgen has also
been shown to inhibit 3bHSD and SRD5A, two other enzymes
involved in androgen synthesis. Furthermore, D4A has
increased inhibition of prostate cancer xenograft growth
compared to the parental abiraterone [13].
In regards to its efficacy, the COU-AA-302 trial showed a
4.4-month survival benefit with abiraterone in
chemotherapy-naive CRPC patients and in patients who had
progressed after docetaxel therapy, the phase III trial COU-
AA-301 demonstrated a 3.9-month survival benefit of abir-
aterone/prednisone over placebo/prednisone [11,14,15].
Despite these promising improvements in patient longevity,
nearly a third of patients have primary resistance to abir-
aterone and even those who initially benefit from treatment
will progress in their disease by 15 months of therapy [11].
As with abiraterone, enzalutamide also functions to
reduce AR signaling. Instead of blocking production of its
ligand, however, enzalutamide binds directly to the AR to
inhibit its activation by androgens. Furthermore, enzalu-
tamide inhibits AR translocation to the nucleus, co-
activator recruitment, and binding of the AR to DNA, all
of which reduce the activation of downstream AR targetgenes [16]. Despite the fact that enzalutamide has been
demonstrated to provide nearly 5 months improved survival
compared to placebo treated individuals in CRPC patients
who failed docetaxel treatment and is also effective in pre-
chemotherapy hormone-naı¨ve prostate cancer patients, as
many as one fourth of patients have primary resistance to
enzalutamide and all patients had progressed by 24 months
of initiating treatment [17,18].
2.2. Taxanes
Docetaxel and cabazitaxel both belong to a class of che-
motherapeutics called taxanes. Docetaxel has traditionally
been the first-line therapy for patients with CRPC. The
introduction of enzalutamide and abiraterone, however,
has led to a decrease docetaxel use as the primary treat-
ment for CRPC. In addition to its use in CRPC, docetaxel has
also proven to be effective in conjunction with ADT in
hormone-naı¨ve prostate cancer patients with high volume
or visceral metastases, providing a 17-month survival
advantage over ADT alone [19]. Docetaxel functions by
binding free tubulin in cells which causes the formation of
stable microtubules and prevents depolymerization,
resulting in inhibition of mitosis and consequent induction
of apoptosis [20e22]. Interestingly, docetaxel has also been
demonstrated to reduce AR expression in CRPC cells which
could further slow the growth of prostate cancer cells [23].
Cabazitaxel, on the other hand, is primarily used in pa-
tients who have failed docetaxel therapy. The TROPIC trial
observed a 2.4-month survival benefit over mitoxantrone in
patients with metastatic CRPC whose disease had pro-
gressed on docetaxel [24]. While both of these drugs are
anti-mitotic and inhibit the division of proliferating cells
through binding tubulin, unique mechanisms of action have
been identified [25].
3. Mechanisms of resistance
While the drugs used for the treatment of CRPC have
distinct methods of action and each has individual
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cross-over in the pathways CRPC cells use to overcome drug
treatment, particularly in the case of the anti-androgens.
The resistance mechanisms can be broken up into several
broad categories (Fig. 1), a number of which will be dis-
cussed below.
3.1. Androgen receptor splice variants
AR splice variants can be formed by genome rearrangement
and alternative splicing involving splicing factors such as
hnRNPAs [26,27]. Most commonly, AR variants lack the C-
terminal ligand-binding domain and these truncated ver-
sions of AR are often ligand-independent and result in
constitutive activation and uncontrolled downstream AR
signaling [28e32]. While AR variant expression is associated
with poorer prognosis and the development of CRPC, the
functional implications of AR variants are not yet fully un-
derstood, due in part to the lack of reliable variant specific
antibodies [33]. Analysis of in vitro prostate cancer cell
lines has determined that nearly all CRPC lines display some
level of AR variant expression and in fact, CWR22Rv1 cells
have nearly equal expression of full length AR and AR var-
iants. Furthermore, prostate cancer bone metastases have
been found to have high AR variant expression [33].
Expression of these AR variants is strongly associated with
resistance to both abiraterone and enzalutamide, and
though not as well studied, to docetaxel resistance as well.
Themost widely studied of these variants, AR-V7, appears to
be of particular importance. It has been shown that AR-V7
expression in patients treated with enzalutamide or abir-
aterone correlates to a significantly lower prostate specific
antigen (PSA) response, shorter progression-free and overall
survival compared to men who do not express AR-V7 [34].
Targeting AR variant expression is one way in which
restoring sensitivity to anti-androgens can be achieved and
a number of clinical trials are currently under way inves-
tigating various therapies to reduce AR variant expression
and improve patient treatment response. Niclosamide, the
anti-helminthic drug, has been demonstrated to preferably
reduce expression of AR-V7 over full length AR, in enzalu-
tamide resistant cells with comparatively high endogenous
AR-V7 expression. Liu et al. [35,36] determined that
niclosamide could induce AR-V7 protein degradation and
reduce recruitment of AR-V7 to promoter regions of target
genes resulting in reduced transcriptional activity and
resensitize resistant cells to enzalutamide and abiraterone
treatment. Furthermore, niclosamide had significant anti-
tumor activity in a number of AR variant expressing CRPC
cell lines such as enzalutamide resistant C4-2B cells (C4-2B
MDVR) and CWR22Rv1 cells, as well as in an enzalutamide
and abiraterone resistant CWR22Rv1 xenograft model. The
combination of niclosamide with either enzalutamide or
abiraterone produced maximal tumor inhibition in a
CWR22Rv1 xenograft model. Based on these encouraging
preclinical data, a phase II study with a leadein safety
phase of abiraterone in combination with niclosamide in a
CRPC clinical trial was launched in 2016 at the University of
California, Davis (NCT02807805). In this trial, recurrent or
metastatic CRPC patients will receive abiraterone 1000 mg
daily with prednisone 5 mg twice daily plus escalating dosesof oral niclosamide/PDMX1001 (400 mg twice daily, 800 mg
twice daily). Exploratory analysis of AR-V7 will also be
conducted in this trial.
Other studies have also found that inhibiting AR variant
expression can improve the response to enzalutamide;
Nadiminty et al. [26] determined that downregulation of
the splice factor hnRNPA1 reduced AR-V7 expression and
consequently sensitized cells to treatment. Inhibition of
HSP90 with onalespib was also observed to alter AR splicing
and lower the expression of AR-V7 [37]. Furthermore,
Yamashita et al. [38] were able to reduce CWR22Rv1
xenograft tumor growth by the addition of ASC-J9, a drug
that degrades AR-V3 and full length AR.
Promising progress has also been made in developing
drugs that target the N-terminus. This includes EPI and its
derivatives. EPI covalently binds the N-terminal domain of
both AR and its variants and inhibits transcriptional activity
to inhibit prostate cancer cell growth in in vivo xenograft
models [39,40]. In vitro and in vivo studies have further
demonstrated that EPI can inhibit the proliferation of
enzalutamide resistant cells [41]. Currently, a phase 1/2
clinical trial is underway (NCT02606123) investigating the
use of EPI in men with metastatic CRPC who have pro-
gressed on enzalutamide or abiraterone [42]. This study will
determine the safety and tolerability of orally administered
EPI and PSA response rate as the primary outcomes.
Another class of drugs targeting the N-terminus of the AR,
niphatenones, while able to inhibit transactivation of AR
and its variants, also promoted the formation of gluta-
thione adducts and therefore may not be as viable for
prostate cancer therapy [43].
In regards to the taxanes, studies have demonstrated
that AR-V7 can promote docetaxel resistance: Thadani-
Mulero et al. [44] found that the AR variant ARV-567 was
sensitive to microtubule stabilization induced by taxanes
whereas AR-V7 was unaffected. In addition they showed
that tumor xenografts expressing AR-V7 were resistant to
docetaxel therapy while those with ARV-567 expression
were highly sensitive to docetaxel. To compliment this fact,
Zhang et al. [45] found that docetaxel resistant cell lines
express higher levels of AR-V7 and that transfection of AR-
V7 into LNCaP cells protected them against docetaxel
treatment. Interestingly, this group also saw an induction of
docetaxel resistance when they transfected AR-V567 into
the cells which contradicts what Thadani-Muleroand col-
leagues observed [44]. To further complicate the taxane
and AR variant connection, another study which measured
AR-V7 expression in circulating tumor cells (CTC) of meta-
static CRPC patients found that detection of AR-V7 in these
cells was not correlated with primary resistance to taxanes
[46]. Furthermore, another study in CTC found that pa-
tients with nuclear CTC AR-V7 expression had increased
survival benefit on taxanes compared to therapies directed
AR signaling [47]. The varying results from these studies
suggest that the impact of AR-V7 on taxane resistance may
be model-specific and more study in this area is needed.
3.2. Increased AR activation
Increased activation of the full length AR is also a well-
documented mechanism for promoting drug resistance,
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AR signaling that occurs when cells develop resistance can
be due to a variety of methods including altered steroido-
genesis or overexpression of the receptor itself.
Prolonged exposure to both enzalutamide and abirater-
one incurs alterations in steroidogenesis. The resultant in-
crease in androgen due to up-regulation of and mutations
to enzymes involved in this complicated pathway promotes
activation of the AR and is a likely contributor to both CRPC
progression and anti-androgen resistance. Enzalutamide
resistant prostate cancer cells had upregulated expression
of androgen and its precursors including cholesterol, DHEA
and progesterone. Additionally, genes involved in steroid
biosynthesis are significantly over-expressed in enzaluta-
mide resistant compared to enzalutamide-sensitive
parental cells [48]. Mostaghel et al. [49] detected up to a
4.5-fold increase in enzymes involved in steroidogenesis in
abiraterone treated prostate cancer cells in vitro, including
CYP17A1, AKR1C3, HSD17B3, and SDR5A2. Additionally, the
hyperactive 1245C mutation of HSD3B1 has been observed
in abiraterone-resistant xenograft models [50]. Of the en-
zymes contributing to steroidogenesis, AKR1C3 is of
particular import. Its activation contributes to both abir-
aterone and enzalutamide drug resistance in CRPC patients
and it has been proposed as a biomarker for assessing
prostate cancer progression [48,51]. Liu et al. [48] found
that indomethacin, a nonsteroidal anti-inflammatory drug,
was capable of inhibiting AKR1C3 enzymatic activity and
restored enzalutamide sensitivity in resistant prostate
cancer cells. This suggests that targeting intracrine andro-
gens improves enzalutamide therapy. Based on these
promising preclinical studies, a single-arm phase II trial
with a leadein safety phase to determine the efficacy and
toxicity of an indomethacin and enzalutamide combination
in the treatment of CRPC will be launched at the University
of California, Davis.
Upregulated AR activation can also be the result of
mutations to the AR gene. It is estimated that 10%e30% of
CRPC patients have AR mutations and these mutations can
result in increased coactivator recruitment, and alter
ligand specificity and affinity [52]. The most commonly
identified AR mutation, T878A, occurs most commonly in
response to drugs targeting androgen synthesis, like abir-
aterone [53]. This mutation, and others, are correlated to
decreased ligand specificity of the AR allowing the receptor
to activate in response to a broader range of molecules,
including estrogen and glucocorticoids, that the wildtype
AR is not responsive to [10,54,55]. This could be of impor-
tance to patients receiving abiraterone since prednisone, a
glucocorticoid, is co-administered with the anti-androgen
to counterbalance some of its side effects. Also with abir-
aterone treatment, androgen precursors, including preg-
nenolone and progesterone, have been demonstrated to
accumulate and some of these have also been identified to
bind mutated AR and instigate downstream AR signaling
[55e57]. Furthermore, the F877L mutation of the AR is
associated with changing ligand binding specificity of the
AR to switch from agonist to antagonist activation, causing
enzalutamide to activate the AR instead of inactivate it
[58,59]. The F877L mutation has also been identified in
circulating cell-free DNA samples from patients whose dis-
ease had progressed while receiving enzalutamide or ARN-509, another anti-androgen structurally similar to enzalu-
tamide [60]. Interestingly, Korpal et al. [59] demonstrated
that while the F877L mutation confers resistance to enza-
lutamide in vitro, cells expressing this mutation remain
responsive to bicalutamide.
3.3. Increased AR expression
In addition to an upregulation in androgen synthesis path-
ways and AR mutation, increased AR activation can be
attained through modulation of wildtype AR expression. In
CRPC, the AR is commonly overexpressed however the
method that drives this overexpression is not completely
understood. One mechanism which has recently been
determined is through upregulation of retinoic acid
receptor-related orphan receptor g (ROR-g). ROR-g was
found to be upregulated in CRPC and could drive AR
expression. ROR-g recruited the AR co-activators SRC-1 and
SRC-3 which in turn promoted AR transcription. Further-
more, treatment with ROR-g antagonists suppressed pros-
tate cancer xenograft growth and improved the response to
enzalutamide [61]. Also affecting AR expression, Gao et al.
[62] observed that abiraterone treated patients had higher
ErbB2 activity and this correlated with increased AR
expression in the nucleus, suggesting a potential increase in
AR signaling. They further went on to demonstrate that
abiraterone resistant xenograft models had increased ErbB2
activity and in turn this led to stabilization of AR protein
through PI3K/AKT signaling. By blocking ErbB2 using lapa-
tinib in combination with abiraterone they were able to
enhance treatment response in xenograft models. Mel-
linghoff et al. [63] determined that HER2 and HER3
signaling can increase AR signaling; knockdown of HER2 was
found to inhibit transcription of the AR and both HER2 and
HER3 stabilized the AR and promoted binding to androgen-
response elements (ARE). Another group, Shiota et al. [64],
found that enzalutamide resistant tumors and cells have
increased HER2 expression and that enzalutamide treat-
ment induced HER2 expression in LNCaP cells. Further-
more, they determined that enzalutamide response could
be enhanced by lapatinib through inhibition of the HER2
signaling axis.
The AR also plays a role in the response to taxanes. In
fact, part of the mechanism of action attributed to taxanes
is through modulation of the AR. Taxanes have been
demonstrated to reduce AR expression, nuclear trans-
location, and transcriptional activity [23,65,66]. These ef-
fects can be induced by docetaxel, but not cabazitaxel,
treatment [65,67]. Komura et al. [68] found that expression
of lysine-specific demethylase 5D (KDM5D) is decreased in
CRPC and low expression levels are associated with a poor
patient prognosis. They further determined that knocking
down KDM5D, which regulates AR transcriptional activity,
induced docetaxel resistance in LNCaP cells, which are
normally highly susceptible to docetaxel treatment, sup-
porting a link between the AR and docetaxel sensitivity.
3.4. Androgen receptor co-regulators
A number of molecules have been identified that function
as co-activators or co-repressors for the AR [69]. These co-
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acting on other molecules in the transcription complex
through methylation, phosphorylation, ubiquitylation or
acetylation, and can also act as molecular chaperones and
help with recruitment of transcriptional machinery
[70e72]. The AR co-activator FKBP51 has been observed to
be upregulated in relapsed LAPC-4 tumor xenografts in
castrated mice resulting in increased activation of the AR in
response to ligand [73]. The p300/CBP and the steroid re-
ceptor co-activators (SRC) class of co-activators, which in-
cludes SRC-1, Tif-2, and SRC-3, are also associated with
prostate cancer disease progression and SRC-1 and p300/
CBP have been linked to IL-6 induced androgen-
independent AR activation [74,75].
AR co-activators can also mediate AR activation of
truncated, ligand-independent AR splice variants. In
particular, McGrath et al. [76] demonstrated that the co-
activator FHL2 (four and a half LIM protein 2) interacts
with AR-V7. They determined that AR-V7 activation, as
determined by ARE-luciferase reporter and in the absence
of androgen, was enhanced by FHL2 expression and this
response could not be abrogated by enzalutamide.
3.5. AR independent anti-androgen resistance
While most of the identified mechanisms inducing resis-
tance to the anti-androgens are associated in one way or
the other with increasing androgen signaling, there are also
compensatory pathways that become activated that are
independent of the AR and androgen synthesis. Down-
stream signaling of the glucocorticoid receptor (GR),
another nuclear receptor like the AR, is increased by
treatment with anti-androgens and treatment response to
enzalutamide in prostate cancer patients is inversely
correlated to GR expression. Furthermore, GR mRNA and
protein expressions were found to be upregulated in anti-
androgen resistant tumors and knockdown of the GR in
resistant cells resensitized them to enzalutamide treat-
ment in vitro [77]. These effects are hypothesized to be a
result of the commonality between the GR and AR allowing
the GR to compensate for the reduced AR activity induced
by anti-androgens.
IL-6 has also been proposed to play a role in the response
to enzalutamide; Handle et al. [78] found that
enzalutamide (as well as bicalutamide, another anti-
androgen) up-regulates suppressor of cytokine 4 signaling
3 (SOCS3) mRNA which in turn modulates IL-6/Stat3
signaling. When they knocked down SOCS3, they were
able to reverse an IL-6/enzalutamide induced reduction in
AR target genes. Further implicating IL-6/Stat3 in enzalu-
tamide resistance, Liu et al. [79] found that overexpression
of constitutively active Stat3 induced resistance to enza-
lutamide treatment whereas downregulation of Stat3
improved enzalutamide response and increased apoptosis.
In another study, Liu et al. [80] also determined that the
drug niclosamide can also down-regulate Stat3 target gene
expression and resensitize enzalutamide resistant cells to
treatment. Wnt/b-catenin signaling is another proliferative
pathway that is upregulated in enzalutamide resistance and
inhibition of this pathway has also been observed to in-
crease enzalutamide sensitivity [81].3.6. Altered drug efflux
A method primarily associated with docetaxel resistance
involves overactivation or overexpression of multidrug
resistance proteins (MDRP). These proteins, including
ABCB1, serve as pumps on the cell membrane to excrete
exogenous compounds, such as docetaxel, out of the cell.
This results in a lower intracellular drug concentration and
a loss of drug efficacy. Multiple studies have shown that
docetaxel resistant cells express significantly increased
levels of ABCB1 compared to docetaxel sensitive parental
cells lines [82,83]. Hour et al. [84] determined that the
increase in ABCB1 observed in docetaxel resistant cells is
likely due in part to the increased epidermal growth factor
receptor (EGFR) expression also found in these cells. Others
have observed that an increase in expression and phos-
phorylation of breast cancer resistance protein, another
transporter protein, promotes docetaxel resistance as well
[85].
Regulating these drug efflux pathways has been an area
of intense study for resensitizing prostate cancer cells to
docetaxel treatment. A number of phase I and II clinical
trials have investigated the possibility of using MDRP
inhibiting drugs, such as elacridar, in combination with
chemotherapy. Despite phase I trials showing promise, only
minimal clinical activity was observed in phase II trials
[86,87]. In vitro and in vivo studies have found that ABCB1
activity and/or expression can be reduced by a variety of
dietary flavonoids including apigenin, naringenin, and
genistein [83,88]. Treatment of docetaxel resistant C4-2B
cells with apigenin was observed to overcome ABCB1
mediated docetaxel resistance and resensitize cells to drug
treatment by reducing ABCB1 expression [83]. In a separate
study, Zhu et al. [89] also determined that anti-androgens
could reduce ABCB1 activity as assayed by Rhodamine 123
efflux. Furthermore, co-treatment in both AR-positive and
AR-negative docetaxel resistant mouse xenograft models
with bicalutamide and docetaxel was observed to signifi-
cantly reduce tumor growth, indicating that this effect by
bicalutamide is independent of AR status.
3.7. b-tubulin dysregulation
Also specific to taxane resistance, the presence of b-tubulin
isoforms promotes both docetaxel and cabazitaxel resis-
tance in prostate cancer. Specifically, taxanes have
reduced efficiency for binding to the class III b-tubulin
isoform [90,91]. Studies have also found increased expres-
sion of class IV b-tubulin and mutations to class 1 b-tubulin
which results in impaired polymerization in docetaxel
resistant cells [92,93]. Galletti et al. [94] found that ETS-
related gene (ERG) overexpression in prostate cells leads
to cabazitaxel resistance both in vitro and in vivo by
interacting with b-tubulin and tubulin dimers. They further
determined that cytoplasmic interruption of this interac-
tion restores cabazitaxel sensitivity. Additionally, sup-
pressed expression of b-tubulin isoform IVa by the synthetic
estrogen diethylstilbestrol has been demonstrated to
enhance tumor growth inhibition in combination with
docetaxel in prostate cancer xenograft models [95]. Others
have demonstrated that the N-terminal domain of the AR
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small-molecule inhibitor EPI improved docetaxel effec-
tiveness and reduced the number of cells displaying the
epithelial-mesenchymal-transition (EMT) phenotype
[96,97].
3.8. Cell survival/growth pathways and cytokines
Most prostate cancer cells that display resistance to one
drug therapy or another have aberrant regulation of mol-
ecules involved in cell survival and death. Specifically,
docetaxel resistance is associated with overexpression of
signal transducers and activator of transcription (Stat) 1,
Stat3, clusterin, heat shock proteins (HSP), GATA2, and
nuclear factor kappa B (NF-kB) [82,98e103]. Reduced ac-
tivity and expression of wildtype p53 has also been linked to
docetaxel insensitivity [104]. Furthermore, expression of
pro-inflammatory cytokines, such as interleukin (IL)-6, IL-8
chemokine ligand 2 (CCL2), transforming growth factor-b1
(TGF-b1) and macrophage inhibitory cytokine-1 (MIC-1)
have been shown to promote docetaxel resistance
[105e109].
In many cases, correcting the aberrant expression of
these molecules has been demonstrated to reintroduce
sensitivity to docetaxel treatment. For instance, inhibition
of IGF1R expression, a molecule downstream of GATA2
signaling, was observed to improve both docetaxel and
cabazitaxel sensitivity in resistant cell lines [103]. Modu-
lating cytokine expression has also proven effective
in vitro; reducing IL-6 and TNFa and inhibiting NF-kB
expression using either synthetic or naturally occurring
compounds results in an increased response to docetaxel in
prostate cancer cells [82,110].
4. Conclusion
Resistance to the current therapies available for CRPC is
inevitable. The variety of adaptive mechanisms by which
this resistance occurs makes overcoming treatment resis-
tance a challenging dilemma. Fortunately, numerous
studies have identified several of these aberrantly func-
tioning pathways and have put forth treatment strategies
for how to best re-introduce sensitivity. With a more thor-
ough understanding for how drug resistance occurs, novel
therapies can be developed and tested for likely thera-
peutic benefits.
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